Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

7792 ARTÍCULOS , VIENDO DEL 4996 AL 5010

BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals 2025, 18, 185

Sikiric P, Seiwerth S, Skrtic A, Staresinic M, Strbe S, Vuksic A, Sikiric S, Bekic D, Soldo D, Grizelj B, Novosel L, Beketic Oreskovic L, Oreskovic I, Stupnisek M, Boban Blagaic A, Dobric I.

Pharmaceuticals (Basel). 2025 Sep 28;18(10):1450. doi: 10.3390/ph18101450.

Monoamine Oxidase Inhibitors in Drug Discovery Against Parkinson's Disease: An Update

Ribeiro LV, Massuda LE, Gontijo VS, Viegas C Jr.

Pharmaceuticals (Basel). 2025 Oct 10;18(10):1526. doi: 10.3390/ph18101526.

The Neuroprotective Potential of Vitamin D(3)

Pietruszkiewicz J, Mrozek K, Zwierz M, Wińska A, Suprunowicz M, Oracz AJ, Waszkiewicz N.

Nutrients. 2025 Oct 12;17(20):3202. doi: 10.3390/nu17203202.

Inter-Organ Crosstalk in Neurodegenerative Disease

Carata E, Destino M, Tenuzzo BA, Panzarini E.

Life (Basel). 2025 Sep 24;15(10):1499. doi: 10.3390/life15101499.

Letter Concerning Biallelic Variants in EPG5 Gene Are Associated with Parkinson's Disease

Dafsari HS, Deneubourg C, Singh K, Maroofian R, Duchen MR, Antebi A, Houlden H, Fanto M, Jungbluth H.

Ann Neurol. 2025 Dec;98(6):1404-1405. doi: 10.1002/ana.78081. Epub 2025 Oct 29.

Reply to "Biallelic Variants in EPG5 Gene Are Associated With Parkinson's Disease"

Li Y, Tang F, Tang B, Qiu J, Sun Q.

Ann Neurol. 2025 Dec;98(6):1405-1406. doi: 10.1002/ana.78080. Epub 2025 Oct 29.

Nano-antioxidants for neurodegenerative disorders: a scoping review

Talaat M, Hassan H, Mosilhy EA, Taha NA, Elsaid M, Sharafeldin MN, Ghallab YK, Lotfy MA, Abdelqawy MA, Ahmed AA, Soliman ME.

Discov Nano. 2025 Oct 29;20(1):194. doi: 10.1186/s11671-025-04320-9.

The effects of RBD medications on dream content: A critical review of evidence

Bontempi G, Capriglia E, Bernardi G, Elce V.

Sleep Med. 2025 Dec;136:106878. doi: 10.1016/j.sleep.2025.106878. Epub 2025 Oct 21.

Unveiling a rare case: Novel TBK1 variant mimicking as multiple system atrophy-like phenotype

Madhavi K, Kandadai RM, Kola S, Borgohain R, Prasad VVSRK.

Parkinsonism Relat Disord. 2025 Dec;141:108102. doi: 10.1016/j.parkreldis.2025.108102. Epub 2025 Oct 25.

Therapeutic innovation through drug repurposing: A multidimensional approach toward treating Parkinson's disease

Sahoo SS, Paidesetty SK, Sahu PK, Pattanaik S, Dandela R.

Bioorg Chem. 2025 Nov;166:109129. doi: 10.1016/j.bioorg.2025.109129. Epub 2025 Oct 25.

Mobile health technologies for the management of Parkinson's disease

Bougea A.

Expert Rev Neurother. 2025 Dec;25(12):1425-1433. doi: 10.1080/14737175.2025.2580468. Epub 2025 Oct 29.

Placebo effects and emotion regulation: conceptual and neural similarities and differences

Bo K, Wager TD.

Handb Clin Neurol. 2025;213:17-29. doi: 10.1016/B978-0-443-29884-4.00004-2.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias